Search Results
Your search for ,ARE matches 21445 pages
Showing 11401 - 114502018 GU CANCERS SYMPOSIUM: Early-Phase Trial of Glutaminase Inhibitor CB-839 in Combination With Cabozantinib or Everolimus in Renal Cell Carcinoma
Data on CB-839, a first-in-class glutaminase inhibitor, will be presented by Tannir et al at the 2018 Genitourinary Cancers Symposium in San Francisco (Abstract 603). The data are from the CX-839-001 study, which includes cohorts evaluating the safety, efficacy and recommended phase II dose of ...
2018 GU CANCERS SYMPOSIUM: Combination Therapy Shows Antitumor Activity in Advanced Renal Cell Carcinoma
Combining the antiangiogenic agent axitinib (Inlyta) with the immunotherapy pembrolizumab (Keytruda) was found to have promising antitumor activity and no unexpected side effects in an early-phase clinical trial in patients with advanced kidney cancer who had not been previously treated. The full...
Gateway for Cancer Research Renews Commitment to Young Investigators
Gateway for Cancer Research has renewed and expanded its support for the Conquer Cancer Foundation Young Investigator Award Program. The organization will underwrite the Gateway for Cancer Research Young Investigator Award (YIA) for each of the next 3 years to enable promising physician-scientists...
Now Available: Limited Edition Conquer Cancer Foundation Nike Sneakers
PURCHASE A PAIR of limited-edition ASCO’s Conquer Cancer Foundation Nike Roshe LD-1000 sneakers, available exclusively from Conquer Cancer. The sneakers celebrate 15.5 million cancer survivors across the United States, and are a great way to start the new year on the right foot! Sizes are limited; ...
CancerLinQ LLC Partners With the National Society of Genetic Counselors
CancerLinQ LLC and the National Society of Genetic Counselors (NSGC), the professional society for genetic counselors, announced that they have entered into a strategic alliance. With the collaboration, NSGC leaders and members will provide expertise to CancerLinQ®, ASCO’s health information...
ASCO Offers Oncology Perspective on 2018 Federal Agency Activities and Rulemaking
AS 2017 came to a close, ASCO offered the oncology community’s perspective to federal agencies—including the Centers for Medicare & Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA)—in response to open comment periods before rules and plans for 2018 and 2019 programs and ...
ASCO Names Adoptive Cell Immunotherapy as Cancer Advance of the Year
In Clinical Cancer Advances 2018: ASCO’s Annual Report on Progress Against Cancer, which highlights the most impactful cancer research progress and the importance of federally funded research, ASCO recognized a type of adoptive cell immunotherapy—chimeric antigen receptor (CAR) T-cell therapy—as...
ASCO/CCO Focused Guideline Update on Role of Bone-Modifying Agents in Metastatic Breast Cancer
AS REPORTED BY Catherine Van Poznak, MD, FASCO, of the University of Michigan, Ann Arbor, and colleagues in the Journal of Clinical Oncology, ASCO and Cancer Care Ontario (CCO) have collaborated in providing a focused update for the ASCO clinical practice guideline on the role of bone-modifying...
Avelumab in Advanced Urothelial Carcinoma: Further Study Needed to Clarify its Role
AS REVIEWED in this issue of The ASCO Post, Patel and colleagues have presented data from the phase I JAVELIN study evaluating avelumab (Bavencio) in platinum-refractory patients with advanced urothelial carcinoma.1 The drug is active with durable responses when compared with historical...
Pembrolizumab Active in Thymic Carcinoma
In a single-center phase II study reported in The Lancet Oncology, Giaccone et al found that pembrolizumab (Keytruda) produced durable responses in patients with recurrent thymic carcinoma. Study Details In the study, 40 evaluable patients with advanced disease progressing after at least one line ...
EXPERT POINT OF VIEW: Eric P. Winer, MD, FASCO; Heikki Joensuu, MD; and Julie Gralow, MD, FASCO
IN INTERVIEWS with The ASCO Post and in discussions held during the meeting, several breast cancer experts weighed in on the findings of GeparSepto and CALGB 40502. Eric P. Winer, MD, FASCO, Chief of the Division of Women’s Cancers and the Thompson Senior Investigator in Breast Cancer Research at ...
Updates of Key Studies Differ on Relative Benefit of Nab-Paclitaxel in Breast Cancer
TWO IMPORTANT STUDIES, both updates of earlier findings and presented at the 2017 San Antonio Breast Cancer Symposium, provided different findings as to the relative benefit of nanoparticle albumin-bound (nab)-paclitaxel (Abraxane), vs solvent-based paclitaxel in breast cancer. “The two studies...
EXPERT POINT OF VIEW: Julie Gralow, MD, FASCO
JULIE GRALOW, MD, FASCO, Director of Breast Medical Oncology for the Seattle Cancer Care Alliance and Professor of Medical Oncology at the University of Washington School of Medicine, commented on the findings of the SUCCESS A trial in an interview with The ASCO Post. The Oxford meta-analysis...
Adjuvant Zoledronic Acid in Early Breast Cancer: Is 5 Years Better?
THE PHASE III SUCCESS A trial, presented at the 2017 San Antonio Breast Cancer Symposium, found no benefit for extending the use of intravenous zoledronic acid from 2 years to 5 years.1 “At this time point, our study showed no difference in disease-free survival or overall survival between 5 years ...
EXPERT POINT OF VIEW: C. Kent Osborne, MD, and Joseph Sparano, MD
“ONCOLOGISTS WANT to find drugs that will delay the use of chemotherapy, and cyclin-dependent kinase (CDK) 4/6 inhibitors provide that. These agents work better than chemotherapy and with less toxicity,” said press conference moderator C. Kent Osborne, MD, Director of the Duncan Cancer Center at...
CDK 4/6 Inhibitors May Be Effective but More Toxic in Older Women
OLDER WOMEN with breast cancer derive benefit from treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors as part of initial endocrine-based therapy for hormone receptor–positive, HER2-negative, metastatic breast cancer, according to a retrospective pooled subgroup analysis of women aged 70 or ...
EXPERT POINT OF VIEW: William Sikov, MD, and Carlos L. Arteaga, MD
BREAST CANCER EXPERTS found the small differences in benefit for 1 year vs 9 weeks of adjuvant trastuzumab (Herceptin) in the SOLD trial to be provocative. William Sikov, MD, of Women and Infants Hospital of Rhode Island’s Breast Health Center and the Warren Alpert Medical School of Brown...
Precision Medicine: Hope or Hype?
ALTHOUGH PRECISION medicine may be a recent discovery in some fields, it is an old story in the field of breast cancer, and one that has been exceptionally important in terms of managing the disease, according to George Sledge, MD, FASCO, Professor of Medicine and Medical Oncologist at the...
EXPERT POINT OF VIEW: Neil P. Shah, MD, PhD; Joseph M. Connors, MD; and Kenneth C. Anderson, MD
NEIL P. SHAH, MD, PhD, Leader of the Hematopoietic Malignancies Program at the University of California, San Francisco, Helen Diller Family Cancer Comprehensive Cancer Center, noted that BLU- 285 could fill an “unmet medical need” for a KIT inhibitor that is “both potent and selective.” He pointed ...
Novel Agent Appears Active in Advanced or Aggressive Systemic Mastocytosis
THE INVESTIGATIONAL agent BLU-285 (avapritinib) has shown significant activity in patients with advanced or aggressive forms of systemic mastocytosis, a rare blood disorder that originates in mast cells, according to the findings of a phase I trial reported at the 2017 American Society of...
EXPERT POINT OF VIEW: Dan Vogl, MD
SESSION MODERATOR Dan Vogl, MD, Assistant Professor of Medicine at the University of Pennsylvania, Philadelphia, told The ASCO Post that the results with 11-1F4 were “very impressive” adding “everyone is excited” about the investigational amyloid-targeting monoclonal antibodies. “These drugs don’t ...
Amyloid-Targeting Antibody Elicits Organ Responses in Patients With Amyloidosis
IN PREVIOUSLY treated patients with amyloid light-chain (AL) amyloidosis, the chimeric fibril-reactive monoclonal antibody 11-1F4 (CAEL-101) produced organ responses in about two-thirds of patients in a phase Ia/b trial reported at the 2017 American Society of Hematology (ASH) Annual Meeting &...
EXPERT POINT OF VIEW: Dan Vogl, MD
MYELOMA SPECIALIST Dan Vogl, MD, Assistant Professor of Medicine at the University of Pennsylvania, Philadelphia, told The ASCO Post that the potential use of daratumumab (Darzalex) in amyloid light-chain amyloidosis is “exciting.” The drug could answer an unmet need in relapsed disease and become ...
Daratumumab Shows Efficacy in Amyloid Light-Chain Amyloidosis
DARATUMUMAB (DARZALEX) may be an effective treatment for systemic amyloid light-chain (AL) amyloidosis, according to phase II studies reported at the 2017 American Society of Hematology (ASH) Annual Meeting & Exposition.1,2 While the cohorts were small and the arms uncontrolled, the findings...
CONCORD-3: Global Surveillance of Cancer Survival Trends, 2000–2014
In an article in The Lancet, Allemani et al reported findings from the CONCORD program for global surveillance of cancer survival trends updated through 2014 (CONCORD-3). Study Details CONCORD-3 includes data on 37.5 million patients diagnosed with cancer between 2000 and 2014 from...
Superior Progression-Free Survival With First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in NSCLC With High Tumor Mutation Burden
The ongoing phase III CheckMate-227 study met its coprimary endpoint of progression-free survival with a combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) vs chemotherapy in patients with first-line advanced non–small cell lung cancer (NSCLC) whose tumors have a high (≥ 10...
For Patients Treated for Myeloma, Antibiotic Prophylaxis May Reduce Infections and Deaths
IN PATIENTS undergoing treatment of multiple myeloma, the prophylactic use of levofloxacin significantly reduced febrile episodes and deaths, without increasing healthcare-associated infections or carriage of key nosocomial pathogens, in a large multicenter study from the United Kingdom.1 The...
Possible Link Between Drinking Hot Tea and Increased Chance of Esophageal Cancer in High-Risk Individuals
Esophageal cancer is the eighth most common cancer worldwide, with an estimated 456,000 new cases in 2012, and the sixth most common cause of death from cancer with an estimated 400,000 deaths, according to data from GLOBOCAN, which provides statistics on the incidence and mortality of cancer...
ASCO Clinical Practice Guideline: Treatment of Malignant Pleural Mesothelioma
As reported by Hedy L. Kindler, MD, of the University of Chicago, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on treatment of malignant pleural mesothelioma. The guideline was informed by a systematic literature search and expert panel review ...
Patient Refusal of Esophagectomy and Long-Term Survival
Patients with esophageal cancer who refuse surgery when it is recommended are less likely to survive long term than similar groups of patients who undergo an operation, according to research presented by Ghaly et al at the 54th Annual Meeting of The Society of Thoracic Surgeons (P78). ...
Scientific Statement From the American Heart Association Examines Intersection of Breast Cancer and Cardiovascular Disease
Patients with breast cancer may be at an increased risk of cardiovascular diseases, including heart failure, and may benefit from a treatment approach that weighs the benefits of specific therapies against potential damage to the heart, according to a new scientific statement from the American...
NCCN Awards Nine Grants for Quality Improvement in Breast Cancer Care
THE NATIONAL COMPREHENSIVE Cancer Network® (NCCN®) Oncology Research Program in collaboration with Pfizer Global Medical Grants announced they have awarded funding to nine projects that use clinical care pathways to implement quality improvement initiatives along the continuum of care for...
2018 GU CANCERS SYMPOSIUM: Adding Immunotherapy to Standard Treatment Slows Growth of Advanced Kidney Cancer—With Fewer Side Effects
In a phase III clinical trial of patients with previously untreated metastatic renal cell cancer combining the immunotherapy atezolizumab (Tecentriq) with the targeted therapy bevacizumab (Avastin) delayed cancer growth by about 3 months longer than sunitinib, another targeted therapy. The benefit...
2018 GU CANCERS SYMPOSIUM: New Model Predicts Survival for People With Bladder Cancer Receiving Immunotherapy
Researchers have developed a model to predict overall survival for people with advanced urothelial cancers treated with the immune checkpoint inhibitor atezolizumab (Tecentriq). The model, which is based on six clinical factors, may help inform treatment decisions for use of atezolizumab in these...
2018 GU CANCERS SYMPOSIUM: Apalutamide Delays Prostate Cancer Metastases by More Than 2 Years
Findings from the phase III placebo-controlled SPARTAN trial suggest that apalutamide is an effective treatment for men with nonmetastatic castration-resistant prostate cancer who are at high risk for developing metastatic disease and for whom no approved treatments exist. Men who received...
EXPERT POINT OF VIEW: Stephen Leong, MD
STEPHEN LEONG, MD, of the University of Colorado Comprehensive Cancer Center, Aurora, discussed the RAINFALL findings at the symposium, commenting, “The study did meet its primary endpoint of progression-free survival; however, it was disappointing not to see a benefit in overall survival or...
Ramucirumab/Chemotherapy in Gastric Cancer: ‘Positive’ Trial but Insufficient Benefit
BASED ON EFFICACY seen in the second-line setting for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma, ramucirumab (Cyramza) was evaluated as first-line therapy in the international phase III RAINFALL trial. Although the study met its primary endpoint, with a 25%...
Bone-Modifying Agents in Metastatic Breast Cancer: Time to De-escalate Dosing Intervals
AS REVIEWED in this issue of The ASCO Post, ASCO and Cancer Care Ontario (CCO) have issued an updated guideline on the role of bone-modifying agents in metastatic breast cancer.1 The updated guideline supports a change in clinical practice for our patients with breast cancer and bone metastasis....
Changing Negative Perceptions on the Impact of Clinical Trials in Brazil
CLINICAL TRIALS are an essential research tool to advance medical knowledge and patient care. Traditionally, the majority of pharmaceutical-sponsored clinical trials have been implemented in Western Europe and North America. More recently, however, large pharmaceutical companies have increased...
EXPERT POINT OF VIEW: Zsofia Kinga Stadler, MD
DISCUSSANT ZSOFIA KINGA STADLER, MD, of Memorial Sloan Kettering Cancer Center, found the nivolumab (Opdivo)/ipilimumab (Yervoy) combination results very encouraging but was also impressed with the monotherapy arm. Both approaches are significant advances in treatment, she said. “The treatment of ...
Nivolumab Plus Ipilimumab Improves Outcomes in Metastatic Colorectal Cancer
IN THE FIRST REPORT of the full cohort of CheckMate-142, nivolumab (Opdivo) plus ipilimumab (Yervoy) led to a 1-year overall survival rate of 85% in previously treated patients with metastatic colorectal cancer who have DNA mismatch repair–deficient (dMMR) or microsatellite instability–high...
FDA Approves Radiopharmaceutical for Rare Gastrointestinal Cancers
On January 26, 2018, the U.S. Food and Drug Administration (FDA) approved lutetium Lu-177 dotatate (Lutathera) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The drug is indicated for adult patients with somatostatin receptor–positive GEP-NETs. GEP-NETs can be...
Howard S. Hochster, MD, Joins Rutgers Cancer Institute
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health welcome Howard S. Hochster, MD, an internationally recognized leader in the development of cancer clinical trials, gastrointestinal oncology, and early-phase cancer drugs. In January, Dr. Hochster assumed the role of Associate Director...
Cancer Collaboration Launches New Lung Cancer Patient Registry
The Bonnie J. Addario Lung Cancer Foundation and the American Lung Association’s LUNG FORCE welcome the International Association for the Study of Lung Cancer as a new member of the Lung Cancer Patient Registry, a place to gather and store detailed patient information, providing a real-world view...
Expect Questions About Necessity of Chemotherapy for Early-Stage Breast Cancer
“For patients with early-stage breast cancer, we’ve seen a significant decline in chemotherapy use over the past few years without a real change in evidence,” or in national guidelines and recommendations, reported Allison W. Kurian, MD, MSc, lead author of a study on chemotherapy recommendations ...
Steep Decline in Chemotherapy Use for Early-Stage Breast Cancer
The use of chemotherapy to treat women with early-stage breast cancer “declined markedly over time,” according to analysis of data from 2,926 women between the ages of 20 and 79. The trends documented “are remarkable for their steepness of decline, independent of clinical factors and despite no...
I’m Not a Victim of Cancer
What I thought after feeling a large, hard lump—similar to the feel of a granola bar—in my left breast was that I probably pulled a muscle while playing with my two young children, ages 7 and 5. Cancer never entered my mind until I asked my husband to feel the lump, and he immediately said, with...
The Toxicity of Time
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Up-to-Date Labels for Older Drugs Essential for Appropriate Use
Oncology drug labels, especially those that have been on the market for more than 15 years, may not always be up-to-date. Critical data about safety, efficacy, or prescribing information may be missing. Modernizing the labeling process can correct inaccurate information, add data for indications ...
Fox Chase Researchers Earn Privately Funded Grants for Five Pilot Projects
Neil Johnson, PhD Richard Pomerantz, PhD Vasily Studitsky, PhD Italo Tempera, PhD Kuang-Yi Wen, PhD The Fox Chase Cancer Center is pleased to announce the first winners of its new privately funded pilot project grants. The program supports cutting-edge...
